Fluvoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled study

American Journal of Psychiatry

Volumn 156, Issue 5, 1999, Pages 756-760

  Stein, Murray B ^a,b,c,d   Fyer, Abby J ^a,b,c   Davidson, Jonathan R T ^a,b,c   Pollack, Mark H ^a,b,c   Wiita, Brinda ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Solvay Pharmaceuticals Inc   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILY; HUMAN; INSOMNIA; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOSOCIAL DISORDER; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOCIAL LIFE; SOCIAL PHOBIA;

EID: 0032894805     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Stein MB, Walker JR, Forde DR: Public speaking fears in a community sample: prevalence, impact on functioning, and diagnostic classification. Arch Gen Psychiatry 1996; 53:169-174
2. Stein MB: How shy is too shy? Lancet 1996; 347:1131-1132
3. Magee WJ, Eaton WW, Wittchen H-U, McGonagle KA, Kessler RC: Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry 1996; 53:159-168
4. Stein MB, Walker JR, Forde DR: Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxiety. Am J Psychiatry 1994; 151:408-412
5. Weiller E, Bisserbe J-C, Boyer P, Lepine J-P, Lecrubier Y: Social phobia in general health care: an unrecognised under-treated disabling disorder. Br J Psychiatry 1996; 168:169-174
6. Schneier FR, Heckelman LR, Garfinkel R, Campeas R, Fallon BA, Gitow A, Street L, Del Bene D, Liebowitz MR: Functional impairment in social phobia. J Clin Psychiatry 1994; 55:322-331
7. Safren SA, Heimberg RG, Brown EJ, Holle C: Quality of life in social phobia. Depress Anxiety 1997; 4:126-133
8. Juster HR, Heimberg RG, Holt CS: Social phobia: diagnostic issues and review of cognitive behavioral treatment strategies. Prog Behav Modif 1996; 30:74-98
9. Marks IM: Advances in behavioral-cognitive therapy of social phobia. J Clin Psychiatry 1995; 56(suppl 5):25-31
10. Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ: Cognitive-behavioral and pharmacological treatment of social phobia. Arch Gen Psychiatry 1991; 48:938-945
11. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, German J, Papp L, Davies S, Gully R, Klein DF: Phenelzine vs atenolol in social phobia. Arch Gen Psychiatry 1992;49:290-300
12. Versiani M, Nardi AE, Mindim FD, Alves AB, Liebowitz MR, Amrein R: Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 1992; 161:353-360
13. Fahlen T, Nilsson HL, Borg K, Humble M, Pauli U: Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine: a double-blind placebo-controlled study. Acta Psychiatr Scand 1995; 92:351-358
14. Lott M, Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Katz RJ, Schaettle SC: Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol 1997; 17:255-260
15. Katschnig H, Stein MB, Buller R, International Multicenter Clinical Trial Group on Moclobemide in Social Phobia: Moclobemide in social phobia: a double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 1997; 247:71-80
16. Noyes R Jr, Moroz G, Davidson JRT, Liebowitz MR, Davidson A, Siegel J, Bell J, Cain JW, Curlik SO, Kent TA, Lydiard RB, Mallinger AG, Pollack MA, Rapaport M, Rasmussen SA, Hedges D, Schweizer E, Uhlenhuth EH: Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol 1997; 17:247-254
17. Schneier FR, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz MR: Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 1998; 172:70-77
18. Davidson JRT, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, Wilson WH: Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993; 13:423-428
19. van Vliet IM, Den Boer JA, Westenberg HGM: Psychopharmacological treatment of social phobia: a double-blind, placebo-controlled study with fluvoxamine. Psychopharmacology (Berl) 1994; 115:128-134
20. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW. Mantle JM, Serlin RC: Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995; 152: 1368-1371
21. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I: Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998; 280:708-713
22. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), version 2. New York, New York State Psychiatric Institute, Biometrics Research, 1995
23. Davidson JR, Miner CM, DeVeaugh-Geiss J, Tupler LA, Colket JT, Potts NL: The Brief Social Phobia Scale: a psychometric evaluation. Psychol Med 1997; 27:161-166
24. Liebowitz MR: Social phobia. Mod Probl Pharmacopsychiatry 1987; 33:141-173
25. Leon AC, Shear MK, Portera L, Klerman GL: Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 1992; 27:78-82
26. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296
27. Kessler RC, Stein MB, Berglund P: Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry 1998; 155: 613-619